2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
40
Triple Negative Breast Neoplasms
34
Carcinoma, Non-Small-Cell Lung
11
Carcinoma, Transitional Cell
10
Urinary Bladder Neoplasms
9
Neoplasm Metastasis
8
Lung Neoplasms
5
Brain Neoplasms
5
Endometrial Neoplasms
4
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
3
Glioblastoma
3
Uterine Cervical Neoplasms
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Urothelial Bladder Carcinoma
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Interventions
eribulin
3
Vinorelbine
2
Paclitaxel
2
Epirubicin
2
Doxorubicin
2
Cyclophosphamide
2
trastuzumab deruxtecan
1
tislelizumab
1
taxane
1
sacituzumab govitecan
1
pembrolizumab
1
pamiparib
1
liposomal doxorubicin
1
camrelizumab
1
anlotinib
1
Taxes
1
Precision Medicine
1
Gemcitabine
1
Docetaxel
1
Cisplatin
1
Carboplatin
1
Capecitabine
1
Anthracyclines
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
HER2-negative Breast Cancer
×
sacituzumab govitecan
×
Clear all
NCT06102824
2024-11-25
ORIENTA
Guangdong Provincial People's Hospital
Phase 2
Recruiting
252 enrolled